In human alloreactive CD4+ T-cells, dichloroacetate inhibits aerobic glycolysis, induces apoptosis and favors differentiation towards the regulatory T-cell subset instead of effector T-cell subsets

Eleftheriadis,Theodoros; Sounidaki,Maria; Pissas,Georgios; Antoniadi,Georgia; Liakopoulos,Vassilios; Stefanidis,Ioannis

doi:10.3892/mmr.2016.4912

In human alloreactive CD4+ T-cells, dichloroacetate inhibits aerobic glycolysis, induces apoptosis and favors differentiation towards the regulatory T-cell subset instead of effector T-cell subsets

Authors:
- Theodoros Eleftheriadis
- Maria Sounidaki
- Georgios Pissas
- Georgia Antoniadi
- Vassilios Liakopoulos
- Ioannis Stefanidis
View Affiliations

Affiliations: Department of Nephrology, Medical School, University of Thessaly, 41110 Larissa, Greece
Published online on: February 19, 2016 https://doi.org/10.3892/mmr.2016.4912
Pages: 3370-3376

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although kidney transplantation is the best therapy for end-stage renal disease, rejection remains a concern, and currently available immunosuppressive agents contribute to morbidity and mortality. Thus, novel immunosuppressive drugs are required. Dichloroacetate (DCA) is already used in the treatment of congenital lactic acidosis and characterized by limited toxicity. As DCA inhibits aerobic glycolysis, which is a prerequisite for CD4+ T-cell proliferation and differentiation into effector T-cells, its possible immunosuppressive role in mixed lymphocyte reaction (MLR), a model of alloreactivity, was investigated. Glucose and lactate concentrations were measured in the supernatants, and cell proliferation was assessed immunoenzymatically. CD4+ T‑cells were then isolated from the MLRs and the expression of cleaved caspase‑3, various enzymes involved in glycolysis, and the signature transcription factors of CD4+ T‑cell subsets were evaluated by western blotting. In MLRs, DCA decreased glucose consumption and aerobic glycolysis, while it exerted a negligible effect on cell proliferation. In CD4+ T‑cells, DCA induced apoptosis, and decreased the expression of glucose trasporter‑1, hexokinase II, lactate dehydrogenase‑A and phosphorylated pyruvate dehydrogenase, while it increased total pyruvate dehydrogenase. In addition, DCA increased the expression of transcription factor forkhead box P3, whereas it decreased the expression of T‑box transcription factor TBX21, trans‑acting T-cell-specific transcription factor GATA‑3 and retinoic acid receptor related orphan receptor‑γt. In conclusion, in alloreactive CD4+ T‑cells, DCA inhibits aerobic glycolysis, induces apoptosis and favors differentiation towards the regulatory T‑cell subset. These characteristics render it a promising immunosuppressive agent in the field of transplantation.

View Figures

View References

1	Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ and van Es LA: Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 12:1672–1679. 1997. View Article : Google Scholar : PubMed/NCBI
2	Russell JD, Beecroft ML, Ludwin D and Churchill DN: The quality of life in renal transplantation-a prospective study. Transplantation. 54:656–660. 1992. View Article : Google Scholar : PubMed/NCBI
3	Kalluri HV and Hardinger KL: Current state of renal transplant immunosuppression: Present and future. World J Transplant. 2:51–68. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fox CJ, Hammerman PS and Thompson CB: Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol. 5:844–852. 2005. View Article : Google Scholar : PubMed/NCBI
5	Pollizzi KN and Powell JD: Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol. 14:435–446. 2014. View Article : Google Scholar : PubMed/NCBI
6	Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG and Rathmell JC: Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4⁺ T cell subsets. J Immunol. 186:3299–3303. 2011. View Article : Google Scholar : PubMed/NCBI
7	Eleftheriadis T, Pissas G, Yiannaki E, Markala D, Arampatzis S, Antoniadi G, Liakopoulos V and Stefanidis I: Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells. Hum Immunol. 74:1501–1509. 2013. View Article : Google Scholar : PubMed/NCBI
8	Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int Immunol. 26:673–684. 2014. View Article : Google Scholar : PubMed/NCBI
9	Stacpoole PW: The pharmacology of dichloroacetate. Metabolism. 38:1124–1144. 1989. View Article : Google Scholar : PubMed/NCBI
10	Bian L, Josefsson E, Jonsson IM, Verdrengh M, Ohlsson C, Bokarewa M, Tarkowski A and Magnusson M: Dichloroacetate alleviates development of collagen II-induced arthritis in female DBA/1 mice. Arthritis Res Ther. 11:R1322009. View Article : Google Scholar : PubMed/NCBI
11	Ostroukhova M, Goplen N, Karim MZ, Michalec L, Guo L, Liang Q and Alam R: The role of low-level lactate production in airway inflammation in asthma. Am J Physiol Lung Cell Mol Physiol. 302:L300–L307. 2012. View Article : Google Scholar :
12	Abdelmalak M, Lew A, Ramezani R, Shroads AL, Coats BS, Langaee T, Shankar MN, Neiberger RE, Subramony SH and Stacpoole PW: Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 109:139–143. 2013. View Article : Google Scholar : PubMed/NCBI
13	Stacpoole PW, Kurtz TL, Han Z and Langaee T: Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev. 60:1478–1487. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kankotia S and Stacpoole PW: Dichloroacetate and cancer: New home for an orphan drug? Biochim Biophys Acta. 1846:617–629. 2014.PubMed/NCBI
15	Sato T, Deiwick A, Raddatz G, Koyama K and Schlitt HJ: Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): Influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol. 115:301–308. 1999. View Article : Google Scholar : PubMed/NCBI
16	Eleftheriadis T, Pissas G, Karioti A, Antoniadi G, Antoniadis N, Liakopoulos V and Stefanidis I: Dichloroacetate at therapeutic concentration alters glucose metabolism and induces regulatory T-cell differentiation in alloreactive human lymphocytes. J Basic Clin Physiol Pharmacol. 24:271–276. 2013. View Article : Google Scholar : PubMed/NCBI
17	Shalini S, Dorstyn L, Dawar S and Kumar S: Old, new and emerging functions of caspases. Cell Death Differ. 22:526–539. 2015. View Article : Google Scholar
18	Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J and Green DR: The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 35:871–882. 2011. View Article : Google Scholar : PubMed/NCBI
19	O'Shea JJ and Paul WE: Mechanisms underlying lineage commitment and plasticity of helper CD4⁺ T cells. Science. 327:1098–1102. 2010. View Article : Google Scholar : PubMed/NCBI
20	Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J and Lanvers-Kaminsky C: Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol. 67:647–655. 2011. View Article : Google Scholar
21	Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP and Rathmell JC: The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20:61–72. 2014. View Article : Google Scholar : PubMed/NCBI
22	Evans OB and Stacpoole PW: Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem Pharmacol. 31:1295–1300. 1982. View Article : Google Scholar : PubMed/NCBI
23	Dummer CD, Carpio VN, Goncalves LF, Manfro RC and Veronese FV: FOXP3⁺ regulatory T cells: From suppression of rejection to induction of renal allograft tolerance. Transpl Immunol. 26:1–10. 2012. View Article : Google Scholar
24	Edozie FC, Nova-Lamperti EA, Povoleri GA, Scottà C, John S, Lombardi G and Afzali B: Regulatory T-cell therapy in the induction of transplant tolerance: The issue of subpopulations. Transplantation. 98:370–379. 2014. View Article : Google Scholar : PubMed/NCBI